Quantanosis.ai

Every 40 seconds someone has a stroke in the US, amounting to 800,000 strokes experienced and $72 billion spent on treatment every year!

Despite having effective interventions like clot-busting drugs and endovascular surgery less than 10% of stroke patients get treated quickly.

36 k
Strokes / Year in US
< 10 %
Receive Timely Treatment
$ 72 B
Annual Cost
96 %
Market Opportunity

Join us in saving lives!

If you are an Investor or a stroke physicians Don't hesitate to contact us.

Contact Us

The problem

Every 40 seconds, someone suffers a stroke in the U.S., contributing to over 800,000 cases each year and driving an annual treatment cost of $72 billion.

 

While life-saving interventions like clot-busting drugs and endovascular surgery exist, less than 10% of patients receive these treatments in time—primarily due to critical delays in diagnosis and care.

 

This staggering gap highlights a 96% untapped market opportunity to revolutionize stroke response and drastically improve patient outcomes through faster, more accessible solutions.

Our Solution

Quantanosis.aiTM offers a groundbreaking stroke detection and treatment solution that stands out through its key differentiators: it is non-invasive, operator-independent, portable, and powered by advanced AI for unparalleled precision. Designed for speed and efficiency, our technology enables diagnosis and initiation of treatment in under two minutes—bringing critical care to patients faster, anywhere.
Discover More
  • Non-invasive
  • Portable
  • Operator-Independent
  • AI-Powered Precision
Watch the Video below.

Independent Testing

An independent testing was conducted by Seleon in Fall 2023, showing the effective and safe performance of our technology

Fast

Complete destruction of thrombus/clot within 45 seconds.

Safe

Full destruction with no harmful debris or residue left.

Precise

Precise clot targeting, minimizing damage to surrounding brain tissue.

Rapid

Can quickly restore of blood flow.

Proven, Trusted, and Backed by Science

Quantanosis.aiTM is built on a foundation of scientific rigor, clinical collaboration, and cutting-edge technology. Our solution is developed in partnership with leading neurologists and stroke specialists, backed by peer-reviewed research and validated through pilot studies. With a strong IP portfolio, regulatory roadmap, and a team of seasoned experts in AI, medical devices, and healthcare delivery, we offer investors and physicians a trusted, evidence-based innovation poised to transform stroke care.

  • Advanced Technology
  • Expert Team
  • Strong IP Portfolio
  • Unique Value Proposition
image

Raised Funds

$4M+ Raised from 30+ Leading Stroke Experts

image

Strategic Partnerships

Jacobs Institute, NeuraSignal, etc.

image

Regulatory Progress

FDA Q-Sub completed; IDE pathway initiated

For Doctors

Join a growing network of leading stroke physicians transforming the standard of care with QuantanosisTM. Our non-invasive, AI-powered histotripsy platform is designed to deliver rapid, precise, and safe treatment without the need for surgical expertise—empowering you to treat more patients, faster, and with improved outcomes. Be part of the future of neurointervention and help bring life-saving technology to patients everywhere.

For Investors

QuantanosisTM represents a rare opportunity to invest at the intersection of deep tech, AI, and MedTech innovation. Backed by 30+ top stroke specialists and built by a world-class team, our FDA-pending, robotic stroke treatment platform is poised to disrupt a $5B+ global market. Join us in democratizing access to stroke care—and shaping the next frontier of non-invasive medical technology. Currently Seeking $15-20M to run first in man IDE, continue development and pursue pivotal trial, if interested, please contact us.
Contact Us

Voice Of Trust

What Experts and Investors are saying about us

"QuantanosisTM bridges a critical gap in stroke care. Its platform isn’t just innovative — it’s scalable and built for speed. The team’s translational rigor, from preclinical validation to AI modelling, gives me confidence this can reach the bedside faster than most first-in-class technologies."

Dr. Pascal M. Jabbour MD

Pascal M. Jabbour MD The Angela and Richard T. Clark Distinguished Professor of Neurological Surgery Division Chief of Neurovascular Surgery and Endovascular Neurosurgery Thomas Jefferson University Hospital

"QuantanosisTM is advancing the science of histotripsy and working towards revolutionizing the treatment of acute ischemic stroke caused by a blood clot in the brain. The ability to dissolve a clot using a non-invasive modality will directly impact acute ischemic stroke patients on a global level and provide access to a potentially life changing treatment in regions that do not have the ability to perform the standard of care, invasive mechanical thrombectom."

Dr. Haralabos Zacharatos

Interventional neurologist JFK Neuroscience Institute, Edison, NJ

“What impressed me most about Quantanosis is how precisely it targets clots—without needing a wire. Its AI guidance and real-time vessel modelling offer a whole new way to treat strokes. This isn’t just a new device; it’s a new hope for faster, safer, and more effective clot removal. It truly feels like the future of stroke care.”

Dr. Victoria Parada MD

Neurology Medical Director Valley Baptist Medical Center - Neurosciences Harlingen Texas

"QuantanosisTM offers a revolutionary approach to acute stroke management: non-invasive, accessible, simple. Its impact on lessening the burden from the leading cause of disability worldwide could be tremendous."

Dr Mikayel Grigoryan MD, FSVIN

Regional Director, Neurointervention, Adventist Health Southern California Adjunct Associate Professor of Neurology, University of Southern California

Frequently Asked Questions

Kindly find below the main FAQs, feel free to contact us for any additional information.

What problem are you addressing?
  • Stroke is a leading cause of disability and death.
  • Treatment delays are substantial—3-5 hours on average.
  • Only 2-10% of stroke patients receive timely treatment.
  • $72 billion in annual treatment costs
  • What: Histotripsy is a unique image-guided, focused ultrasound technology that relies upon initiation of acoustic cavitation to mechanically homogenize targeted blood cells.
  • How: Histotripsy uses high-intensity pulsed sound waves to induce “bubble clouds” from gases naturally present in targeted blood cells. These bubble clouds form and collapse in microseconds, creating mechanical forces strong enough to lyse a blood clot at cellular and sub-cellular levels in a non-invasive and non-thermal method.
  • Non-Invasive : Histotripsy uses focused sound waves to non-invasively disrupt blood clots.
  • Mechanical Clot Breakdown: It mechanically fragments clots in the MCA, enhancing natural clearance.
  • Precision Targeting: Offers precise clot targeting, minimizing damage to surrounding brain tissue.
  • Rapid Revascularization: Potential to quickly restore blood flow in acute ischemic stroke.
  • Safety with Lower Hemorrhage Risk: Reduces bleeding risks
  • Partnering/acquisition with a strategic neurovascular co.
  • Anyone in the stroke treatment space
  • Comps for recent acquisitions transactions for similar companies and resulting multiples
  • Filed US Patent August 2020
  • Have filed patents in the US, Europe, Switzerland and Japan